Biofrontera Inc. (BFRIW) stock
BFRIWNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BFRI
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026Score 10/30
$0.00+0.00 (0.00%)
Close on Oct 30, 2026Market cap $12.96MP/E –Yield –
Biofrontera operating margin
Operating margin is operating income as a percentage of revenue.
Biofrontera's operating margin for the twelve months ending Jun 30, 2026 was -14.2%. For fiscal 2025 it was -27.2%, against -46.1% the year before. The highest annual figure on record is -27.2% in fiscal 2025.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -27.2% | +18.9 |
| FY2024 | Dec 31, 2024 | -46.1% | +20.4 |
| FY2023 | Dec 31, 2023 | -66.6% | −1.8 |
| FY2022 | Dec 31, 2022 | -64.8% | +39.8 |
| FY2021 | Dec 31, 2021 | -104.6% | −53.6 |
| FY2020 | Dec 31, 2020 | -51.0% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -4.4% | +51.9 |
| Q1 FY2026 | Mar 31, 2026 | -42.8% | +10.1 |
| Q4 FY2025 | Dec 31, 2025 | 26.7% | +40.3 |
| Q3 FY2025 | Sep 30, 2025 | -89.8% | −34.8 |
| Q2 FY2025 | Jun 30, 2025 | -56.2% | +8.4 |
| Q1 FY2025 | Mar 31, 2025 | -52.9% | +16.2 |
| Q4 FY2024 | Dec 31, 2024 | -13.6% | +22.8 |
| Q3 FY2024 | Sep 30, 2024 | -55.0% | −3.1 |
| Q2 FY2024 | Jun 30, 2024 | -64.7% | +84.1 |
| Q1 FY2024 | Mar 31, 2024 | -69.1% | −6.2 |
| Q4 FY2023 | Dec 31, 2023 | -36.5% | +18.9 |
| Q3 FY2023 | Sep 30, 2023 | -51.9% | +32.3 |
| Q2 FY2023 | Jun 30, 2023 | -148.8% | −9.4 |
| Q1 FY2023 | Mar 31, 2023 | -62.9% | −31.0 |
| Q4 FY2022 | Dec 31, 2022 | -55.4% | −34.9 |
| Q3 FY2022 | Sep 30, 2022 | -84.2% | +287.4 |
| Q2 FY2022 | Jun 30, 2022 | -139.4% | −76.4 |
| Q1 FY2022 | Mar 31, 2022 | -31.9% | +42.5 |
| Q4 FY2021 | Dec 31, 2021 | -20.5% | −18.3 |
| Q3 FY2021 | Sep 30, 2021 | -371.6% | −299.5 |
| Q2 FY2021 | Jun 30, 2021 | -63.0% | – |
| Q1 FY2021 | Mar 31, 2021 | -74.4% | – |
| Q4 FY2020 | Dec 31, 2020 | -2.2% | – |
| Q3 FY2020 | Sep 30, 2020 | -72.1% | – |